Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02490943
Other study ID # TRB2015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2015
Est. completion date April 30, 2019

Study information

Verified date January 2019
Source Brown, Theodore R., M.D., MPH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.


Description:

The most common adverse event associated with this subcutaneously (SC) injected drug is injection site reaction (ISR) including redness and pain.Theoretically, both heat and cold modalities may improve interferon injection tolerance. Warm compress before injection may increase local blood flow and increase rapid systemic absorption, while cold compress afterward may reduce the erythema, edema and pain that often follow SC injections. A trial comparing heat-before and cold-after therapy is warranted to determine the relative effectiveness of these modalities. Intervention: Product: Reusable cold and warm compress. Patients will receive written instructions for microwave heating and freezer cooling of the compress. Warm compress: Pre-heating in microwave oven, per instructions. Apply warm compress for 5 minutes prior to injection. The initial compress temperature will be about 43 degrees Celsius (range 40-46 degrees Celsius) and slowly decline during application. Administer drug soon after removal. Cold compress: Cooling in a freezer as per instructions. Soon after drug injection, apply cold compress for 10 minutes. The initial compress temperature will range 15-18 degrees Celsius. - Timers will be utilized to mark 5-minute and 10-minute treatment intervals - Participants will be encouraged to maintain constant practices with regards to non-steroidal anti-inflammatory drug use during the study Study Objectives: 1. To assess and compare the impact on erythema of two thermal treatments: warm compress prior to PEG injection and cold compress following PEG injection 2. To assess the natural history of PEG-erythema over time. This will be accomplished with 18 weeks of observation in the control group.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date April 30, 2019
Est. primary completion date January 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of MS made at least 3 months prior based on McDonald criteria. - Age 18 or more - Ongoing treatment with PEG for 30 days or more at screening - No MS exacerbation for 60 days prior to screening. - Score of =50 on screening ISR Erythema Index - Home access to microwave oven and freezer - Written informed consent Exclusion Criteria: - Any contraindication to warm or cold compress: - Inability to sense temperature change by patient report - Metal implant near injection site (e.g. injection near intra-abdominal baclofen pump) - History of allergy or intolerance to local heat or cold application - Bleeding disorder - Concomitant use of any topical prescription medication at injection site - Females who are breast-feeding, pregnant or have potential to become pregnant during the course of the study (fertile and unwilling/unable to use effective contraceptive measures) - Cognitive deficits that would interfere with the subject's ability to give informed consent or perform study testing. - Any other serious and/or unstable medical condition

Study Design


Intervention

Other:
Warm Compress Before Injection
Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
Cold Compress After Injection
Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.

Locations

Country Name City State
United States Evergreen Health Kirkland Washington

Sponsors (2)

Lead Sponsor Collaborator
Brown, Theodore R., M.D., MPH Evergreen Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline ISR Erythema Index at 24 hours, 7 days, and 14 days every 6 weeks for 18 weeks. Participants will record the diameter of patch of skin discoloration in millimeters, measuring at the maximum width. 24 hours, 7 days, 14 days
Secondary Change from baseline in rating of Modified Local Injection Site Reaction Scale 24 hours
Secondary Erythema score on the Visual Assessment Scale. This is a 5 point visual assessment scale. Participants will be asked to observe the change in skin color at the site of injection. They will rate the intensity of skin color change (erythema) using the scale below. These assessments will be recorded at the following time points: 24 hours, 7 days, and 14 days Change from Baseline in VAS at 24 hours, 7 days, and 14 days.
Secondary Pain score on the visual analogue scale after 10-minutes. (post-injection, 0-10 visual analogue scale (VAS)) 10 min.
Secondary Pain score on the visual analogue scale Post-Injection 24 hours, 7 days, and 14 days (post-injection, 0-10 visual analogue scale (VAS)) Change from Baseline in VAS at 24 hours, 7 days, and 14 days.
Secondary Level of Comfort Post-Injection Impression of Last 3 Weeks. This is a single question: "How would you rate your level of comfort with the last three injections?" This is on a 0-10 VAS with 0= "extremely bad" 5="neither good nor bad" and 10= "extremely good." The question will be answered at the end of each phase of the study. 18 Weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT04290273 - Characterisation of the Time-course Response of UV-induced Erythema N/A
Completed NCT01659853 - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Phase 3
Completed NCT00839462 - Efficacy of Dexpanthenol in Thermic Erythema Phase 2
Not yet recruiting NCT06016361 - Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy N/A
Completed NCT03633877 - Durapore vs. Hy-Tape to Secure The Endotracheal Tube N/A
Active, not recruiting NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Phase 2
Completed NCT06369675 - Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT03352323 - An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Phase 3
Completed NCT06369727 - Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design Phase 1
Completed NCT03041064 - Multiday Beach Study N/A
Completed NCT02832141 - Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems
Completed NCT02131636 - Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Phase 3
Completed NCT01636765 - Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT01124513 - Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI N/A
Terminated NCT03496584 - Effects of Phytonutrients on Vascular Health and Skin in Obese Males N/A
Completed NCT02737592 - A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects N/A
Completed NCT03852563 - A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering N/A
Completed NCT05300542 - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema N/A
Completed NCT03477825 - Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin N/A